ArticleEuropean journal of epidemiology2012
Generalizability of results from the National Lung Screening Trial.
Article in European journal of epidemiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- NLRP3 inflammasome expression affects immune cell infiltration and clinical prognosis inMolecular medicine reports · 2025Article
- Mechanism and role of H. pylori CagA-induced NLRP3 inflammasome in gastric cancer immune cell infiltration.Scientific reports · 2025Article
- Anchoring Filament Protein Ladinin-1 is an Immunosuppressive Microenvironment and Cold Tumor Correlated Prognosticator in Lung Adenocarcinoma.Biochemical genetics · 2023Article
- The prognostic value of NLRP1/NLRP3 and its relationship with immune infiltration in human gastric cancer.Aging · 2022Article
- hnRNPA2B1-Mediated Extracellular Vesicles Sorting of miR-122-5p Potentially Promotes Lung Cancer Progression.International journal of molecular sciences · 2021Article
- Article
- CKS2 Overexpression Correlates with Prognosis and Immune Cell Infiltration in Lung Adenocarcinoma: A Comprehensive Study based on Bioinformatics and Experiments.Journal of Cancer · 2021Article
- CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment.Cancer cell international · 2020Article
- Article
- A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.Cancer research · 2019Article
- Characterization and selective incorporation of small non-coding RNAs in non-small cell lung cancer extracellular vesicles.Cell & bioscience · 2018Article
- Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer.Chronic diseases and translational medicine · 2017Article
- Lung cancer risk and cancer-specific mortality in subjects undergoing routine imaging test when stratified with and without identified lung nodule on imaging study.European radiology · 2015Article
- Smoking, inflammation and small cell lung cancer: recent developments.Wiener medizinische Wochenschrift (1946) · 2015Review
- Implementing lung cancer screening in the real world: opportunity, challenges and solutions.Translational lung cancer research · 2015Review
- Why and how would we implement a lung cancer screening program?Public health reviews · 2015Review
- Implementation of new clinical programs in the VHA healthcare system: the importance of early collaboration between clinical leadership and research.Journal of general internal medicine · 2014Article
- The Rotterdam Study: 2014 objectives and design update.European journal of epidemiology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the major cause of cancer-related death worldwide, with a 5-year survival of only 16%. Most lung cancer cases are diagnosed at an advanced incurable stage. As earlier stages have a better prognosis, the key to reducing mortality could be early diagnosis of the disease. At present, low-dose computed tomographic (CT) screening has shown promising data. Lung cancer death rates were reduced by 20% when CT screening is compared to chest radiography in a high-risk group. There are many advantages of CT screening in lung cancer, however there are also some important issues that should be taken into account. Therefore, the applicability of the results to clinical practice is not clear yet. In this Commentary we discuss different aspects that play important roles in the balance between harms and benefits of screening, including overdiagnosis, availability of treatment options worldwide, ethical considerations, costs, and prolonged life expectancy. We conclude that clinicians should be cautious in generalizing findings to the total population of smokers and take into account that the use of lung cancer screening in clinical practice may have limitations.
Indexed as
Identifiers
22872503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.